乐鱼在线
About Henlius
乐鱼在线:Company Profile
乐鱼在线:Corporate Culture
Honor
Board of Directors
乐鱼在线:Management Team
乐鱼在线:Advisory Committee
Product
Marketed Products
Products in R&D
乐鱼在线:Clinical Trial
Science & Technology
R&D Result
乐鱼在线:Innovation Centre
Technology Platform
Quality Management
乐鱼在线:Manufacturing
Collaborations
Investor Relations
Information Disclosure
乐鱼在线:Corporate Governance
Financial Reports
乐鱼在线:Stock Info
乐鱼在线:IR Calendar
乐鱼在线:Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
乐鱼在线:Multi-media
Media Reports
乐鱼在线:Media Enquiry
Careers
Talent Philosophy
乐鱼在线:Staff Life
Training and Development
乐鱼在线:Contact Us
乐鱼在线:Contact Information
Customer Message
Privacy
乐鱼在线:Legal Statement
乐鱼在线:Compliance
EN
简体
EN
繁體
Home
About Henlius
乐鱼在线:Company Profile
乐鱼在线:Corporate Culture
Honor
Board of Directors
乐鱼在线:Management Team
Advisory Committee
Product
乐鱼在线:Marketed Products
乐鱼在线:Products in R&D
Clinical Trial
乐鱼在线:Science & Technology
乐鱼在线:R&D Result
Innovation Centre
Technology Platform
乐鱼在线:Quality Management
乐鱼在线:Manufacturing
Collaborations
乐鱼在线:Investor Relations
Information Disclosure
乐鱼在线:Listing Documents
乐鱼在线:Announcement & Circulars
乐鱼在线:Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
乐鱼在线:Analyst Coverage
乐鱼在线:Contact Information
Media
乐鱼在线:Press Release
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
乐鱼在线:Multi-media
Company
Event
乐鱼在线:Popular Science
Media Reports
乐鱼在线:Media Enquiry
Careers
Talent Philosophy
Staff Life
乐鱼在线:Training and Development
乐鱼在线:Job Opportunities
Contact Us
Contact Information
乐鱼在线:Customer Message
Privacy
乐鱼在线:Legal Statement
乐鱼在线:Compliance
Be the most trusted biotech company
乐鱼在线:Press Release
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
乐鱼在线:Multi-media
Company
乐鱼在线:Popular Science
乐鱼在线:Highlights
Download
乐鱼在线:Media Reports
乐鱼在线:Media Enquiry
2020-12-17
NMPA Has Accepted The NDA of HLX01(Rituximab Injection) for the Treatment of Rheumatoid Arthritis
2020-12-07
Henlius Adalimumab Biosimilar 汉达远® Approved by NMPA
2020-11-20
Henlius Released Phase 3 Study Data of its Bevacizumab Biosimilar HLX04 at ESMO Asia 2020
2020-11-12
The IND Application of Henlius Daratumumab Biosimilar Accepted by NMPA
2020-11-09
First Patient Dosed in Phase 1 Clinical Trial of Henlius Denosumab Biosimilar HLX14
2020-11-06
Henlius ACE2-Fc Fusion Protein HLX71 Received IND Approval from US FDA
2020-10-29
The Results of the Phase 3 Study of Henlius’ Adalimumab Biosimilar HLX03 Presented on EADV 2020
2020-10-15
Henlius and Essex Enter into a Global Co-Development and Exclusive License Agreement, to Jointly Develop Bevacizumab to Treat Ophthalmic Diseases
2020-10-05
Investigational New Drug Application of Henlius SARS-CoV-2 Neutralizing Antibody HLX70 Approved by US FDA
1
2
3
...
5
var _hmt = _hmt || []; (function() { var hm = document.createElement("script"); hm.src = "https://hm.baidu.com/hm.js?90c4d9819bca8c9bf01e7898dd269864"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })(); !function(p){"use strict";!function(t){var s=window,e=document,i=p,c="".concat("https:"===e.location.protocol?"https://":"http://","sdk.51.la/js-sdk-pro.min.js"),n=e.createElement("script"),r=e.getElementsByTagName("script")[0];n.type="text/javascript",n.setAttribute("charset","UTF-8"),n.async=!0,n.src=c,n.id="LA_COLLECT",i.d=n;var o=function(){s.LA.ids.push(i)};s.LA?s.LA.ids&&o():(s.LA=p,s.LA.ids=[],o()),r.parentNode.insertBefore(n,r)}()}({id:"K9y7iMpaU8NS42Fm",ck:"K9y7iMpaU8NS42Fm"});
乐鱼在线官网-乐鱼在线
ufc下注官网_ufc竞猜平台【新版本下载】
ufc下注_ufc押注网站
ufc下注官网_ufc竞猜软件【注册登录】
天博APP-天博APP下载-天博APP官方网站